Pharmaceutical composition containing homoharringtonine and application of pharmaceutical composition

A technology of homoharringtonine and composition, which is applied in the field of biomedicine and can solve problems such as poor therapeutic effect

Active Publication Date: 2021-04-27
SHENYANG PHARMA UNIVERSITY
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, monotherapy is often ineffective

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing homoharringtonine and application of pharmaceutical composition
  • Pharmaceutical composition containing homoharringtonine and application of pharmaceutical composition
  • Pharmaceutical composition containing homoharringtonine and application of pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0043] Reagents and methods:

[0044] Cells: AML cells HL-60, U937, MV4-11, THP-1 cells were purchased from American Type Culture Collection (ATCC). AML cells MOLM-13 were purchased from DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (Braunschweig Germany). NB4 cells were provided by Dr. Waxman.

[0045] Drugs: The pharmaceutical compositions used in the following examples were all prepared according to the following methods; HHT was purchased from Minsheng Pharmaceutical, and the stock concentration was 1.833 mM; Venetoclax, midostaurin, sorafenib, gilteritinib, crenolanib and quizartinib were all purchased from Selleck.

[0046] Method 1: Accurately weigh venetoclax, midostaurin, sorafenib, gilteritinib, crenolanib, and quizartinib, dissolve them in dimethyl sulfoxide, make 20mM stock solutions, store them at -20°C, and dilute them with culture medium before use. concentration. When using HHT, dilute it to an appropriate concentration with fresh medium. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
elongationaaaaaaaaaa
Login to view more

Abstract

The invention belongs to the technical field of biological medicines, and relates to a pharmaceutical composition containing homoharringtonine (HHT) and an application of the pharmaceutical composition, in particular to the pharmaceutical composition containing the homoharringtonine and an application of the pharmaceutical composition to preparation of a medicine for treating leukemia. The invention particularly relates to an application of a pharmaceutical composition of HHT and a Bcl-2 inhibitor Venetoclax to treatment of AML or an application of the pharmaceutical composition of HHT and an FLT3 inhibitor (midostaurin, sorafenib, gilteritinib, crenolanib or quizartinib) to preparation of a medicine for treating AML of FLT3-ITD mutation. The molar ratio of the homoharringtonine to the venetoclax serving as the Bcl-2 inhibitor ranges from (1: 5) to (4: 1), and the molar ratio of the homoharringtonine to the FLT3-ITD ranges from (1: 5) to (5: 1). The components of the composition can be used at the same time or in any sequence.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and relates to a pharmaceutical composition containing homoharringtonine (HHT) and its application, in particular to a pharmaceutical composition containing homoharringtonine and its application in preparing medicines for treating leukemia. Especially related to the pharmaceutical composition of HHT and Bcl-2 inhibitor venetoclax (venetoclax) for the treatment of AML or HHT and FLT3 inhibitors (midostaurin (midostaurin), sorafenib (sorafenib), gilteritinib ( Application of a pharmaceutical composition of gilteritinib, crenolanib or quizartinib in the preparation of a medicament for treating FLT3-ITD mutated AML. Background technique [0002] Acute myeloid leukemia (AML) is a highly heterogeneous hematologic malignancy. Traditional chemotherapeutic drugs anthracycline and cytarabine are combined to treat AML, and the complete sustained-release rate of patients is >50%. However, only 25%-50...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/55A61K45/06A61K31/437A61K31/553A61K31/44A61K31/497A61K31/4545A61K31/5377A61P35/02
CPCA61K31/55A61K45/06A61K31/437A61K31/553A61K31/44A61K31/497A61K31/4545A61K31/5377A61P35/02A61K2300/00
Inventor 景永奎李盈邱阳华会明赵临襄
Owner SHENYANG PHARMA UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap